Medicus Pharma plans SkinJect combination with undisclosed SPAC

• Medicus Pharma's SkinJect unit signed a nonbinding letter of intent to combine with an undisclosed special purpose acquisition company.
• The proposed deal values SkinJect at $135 million pre-money enterprise value, with 100% acquired in exchange for newly issued common shares.
• SkinJect would become a separately listed company, with its parent seeking to retain majority economic and voting ownership.
• Concurrent equity financing would support the SKNJCT-005 Gorlin syndrome study and preparation and submission of a potential New Drug Application.
• Completion is anticipated in the first half of 2027, subject to definitive agreements, financing and other closing conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040830PRIMZONEFULLFEED9869861) on November 04, 2026, and is solely responsible for the information contained therein.